It was a weaker, er, week for healthcare stocks on the ASX, but takeover bids, clinical trials and expansion deals ... Read ...
Stockhead on MSN
ASX Quarterly Health Wrap: Lumos lands US$317m deal as ReNerve and Vitrafy hit key milestones
Lumos locked in a US$317m US deal, ReNerve hit the market with its first EmpliQ product, and Vitrafy rolled out ... Read More ...
The firm hopes to exploit its first-mover advantage in the OTC space following de novo clearance for an at-home PCR test to detect sexually transmitted infections.
Lumos Diagnostics has kicked off a key paediatric study in the US for its FebriDx rapid diagnostic test, marking a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback